The FDA was notified by Novo Nordisk on April 3, 2025, that several hundred units of counterfeit Ozempic (semaglutide) injection 1mg were in the U.S. drug supply chain. The counterfeit products were distributed outside the Novo Nordisk authorized supply chain in the U.S. FDA seized the identified counterfeit products on April 9, 2025.
FDA is aware of six adverse event reports associated with this lot, however none of them appear to be associated with the counterfeit product. All six adverse events were reported by Novo Nordisk.
FDA and Novo Nordisk are testing the seized products and do not yet have information about the identity, quality or safety of these drugs.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!